The outlook for hATTR-PN can vary depending on the genetic mutation involved and how the condition first presents. Newer treatments are helping improve outcomes. hATTR is a rare, hereditary disease. A ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the first-ever recommendations for patient- and family-centred ...
Zacks Investment Research on MSN
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
Alnylam Pharmaceuticals’ ALNY primary top-line driver is its newest drug, Amvuttra (vutrisiran), which is approved in the United States and the EU for treating the polyneuropathy of hereditary ...
Onpattro (patisiran) is a prescription drug. It’s used to treat polyneuropathy caused by hereditary ATTR (hATTR) amyloidosis. Onpattro is given as an intravenous (IV) infusion by a healthcare ...
CAMBRIDGE, Mass., April 21, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that data from inotersen’s clinical ...
Hereditary ATTR (hATTR) amyloidosis is a rare condition that affects an estimated 50,000 people worldwide. Symptoms can affect multiple parts of the body, including the nervous, cardiac and ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) ...
“Commencing the NDA submission for patisiran is wonderful news for the hereditary amyloidosis community. We are deeply encouraged by the potential impact patisiran can make on the lives of people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback